ArticleBritish journal of cancer2011
Targeting IGF-1R: throwing out the baby with the bathwater?
Article in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.International journal of cancer · 2017Trial
- MCT4 deficiency suppresses tumor incidence and metastasis by downregulating IGF1 expression and enhancing anti-tumor immunity.Communications biology · 2026Article
- Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.British journal of cancer · 2020Article
- Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.Cancer science · 2017Article
- Combine and conquer: challenges for targeted therapy combinations in early phase trials.Nature reviews. Clinical oncology · 2017Review
- Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.Journal of cancer research and clinical oncology · 2015Article
- Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.Frontiers in oncology · 2015Review
- Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly.Current oncology reports · 2014Review
- Theranostic applications of antibodies in oncology.Molecular oncology · 2014Review
- Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Article
- Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.PloS one · 2013Article
- Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.The Lancet. Oncology · 2012Article
- Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.International journal of cancer · 2012Article
- Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations.Sarcoma · 2011Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.